Protection of human corneal epithelial cells from TNF-α- induced disruption of barrier function by rebamipide

Investigative Ophthalmology and Visual Science

Volumn 54, Issue 4, 2013, Pages 2752-2760

  Kimura, Kazuhiro ^a   Morita, Yukiko ^a   Orita, Tomoko ^a   Haruta, Junpei ^b   Takeji, Yasuhiro ^b   Sonoda, Koh Hei ^a  

^a YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OTSUKA PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Barrier; Corneal epithelium; Cytokine; Wound healing

Indexed keywords

BETA CATENIN; I KAPPA B; MYOSIN LIGHT CHAIN; OCCLUDIN; PROTEIN ZO1; REBAMIPIDE; SYNAPTOTAGMIN I; TUMOR NECROSIS FACTOR ALPHA; UVOMORULIN; ALANINE; ANTIOXIDANT; CADHERIN; CTNNB1 PROTEIN, HUMAN; DRUG DERIVATIVE; EYE DROPS; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NF KAPPAB INHIBITOR ALPHA; NF-KAPPAB INHIBITOR ALPHA; OCLN PROTEIN, HUMAN; QUINOLONE DERIVATIVE; TJP1 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL JUNCTION; CONFOCAL MICROSCOPE; CONFOCAL SCANNING LASER OPHTHALMOSCOPE; CONTROLLED STUDY; CORNEA EPITHELIUM; DRY EYE; ELECTRIC RESISTANCE; EYE INFLAMMATION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; IMMUNOFLUORESCENCE MICROSCOPY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; TIGHT JUNCTION; ANIMAL; CELL LINE; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECT; FLUORESCENT ANTIBODY TECHNIQUE; IMPEDANCE; METABOLISM; PATHOLOGY; PHOSPHORYLATION; SPRAGUE DAWLEY RAT; WOUND HEALING;

ADHERENS JUNCTIONS; ALANINE; ANIMALS; ANTIOXIDANTS; BETA CATENIN; CADHERINS; CELL LINE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRY EYE SYNDROMES; ELECTRIC IMPEDANCE; EPITHELIUM, CORNEAL; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; I-KAPPA B PROTEINS; IMMUNOBLOTTING; MALE; NF-KAPPA B; OCCLUDIN; OPHTHALMIC SOLUTIONS; PHOSPHORYLATION; QUINOLONES; RATS; RATS, SPRAGUE-DAWLEY; TIGHT JUNCTIONS; TUMOR NECROSIS FACTOR-ALPHA; WOUND HEALING; ZONULA OCCLUDENS-1 PROTEIN;

MLCS; MLOWN;

EID: 84876472198     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.12-11294     Document Type: Article

References (55)

1. Prausnitz MR, Noonan JS. Permeability of cornea, sclera, and conjunctiva: a literature analysis for drug delivery to the eye. J Pharm Sci. 1998;87:1479-1488.
2. Kinoshita S, Adachi W, Sotozono C, et al. Characteristics of the human ocular surface epithelium. Prog Retin Eye Res. 2001; 20:639-673.
3. Kalinin AE, Kajava AV, Steinert PM. Epithelial barrier function: assembly and structural features of the cornified cell envelope. Bioessays. 2002;24:789-800.
4. Ebnet K, Suzuki A, Ohno S, Vestweber D. Junctional adhesion molecules (JAMs): more molecules with dual functions? J Cell Sci. 2004;117:19-29.
5. Harhaj NS, Antonetti DA. Regulation of tight junctions and loss of barrier function in pathophysiology. Int J Biochem Cell Biol. 2004;36:1206-1237.
6. Prada J, Noelle B, Baatz H, Hartmann C, Pleyer U. Tumour necrosis factor alpha and interleukin 6 gene expression in keratocytes from patients with rheumatoid corneal ulcerations. Br J Ophthalmol. 2003;87:548-550.
7. Collares-Buzato CB, Jepson MA, Simmons NL, Hirst BH. Increased tyrosine phosphorylation causes redistribution of adherens junction and tight junction proteins and perturbs paracellular barrier function in MDCK epithelia. Eur J Cell Biol. 1998;76:85-92.
8. Stevenson BR, Anderson JM, Bullivant S. The epithelial tight junction: structure, function and preliminary biochemical characterization. Mol Cell Biochem. 1988;83:129-145.
9. Anderson JM, Fanning AS, Lapierre L, Van Itallie CM. Zonula occludens (ZO)-1 and ZO-2: membrane-associated guanylate kinase homologues (MAGuKs) of the tight junction. Biochem Soc Trans. 1995;23:470-475.
10. Aberle H, Schwartz H, Kemler R. Cadherin-catenin complex: protein interactions and their implications for cadherin function. J Cell Biochem. 1996;61:514-523.
11. Giehl K, Menke A. Microenvironmental regulation of E-cadherin-mediated adherens junctions. Front Biosci. 2008; 13:3975-3985.
12. Schnittler HJ. Structural and functional aspects of intercellular junctions in vascular endothelium. Basic Res Cardiol. 1998; 93;30-39.
13. Miyoshi J, Takai Y. Molecular perspective on tight-junction assembly and epithelial polarity. Adv Drug Deliv Rev. 2005;57: 815-855.
14. Ban Y, Dota A, Cooper LJ, et al. Tight junction-related protein expression and distribution in human corneal epithelium. Exp Eye Res. 2003;76:663-669.
15. Scott RA, Lauweryns B, Snead DM, Haynes RJ, Mahida Y, Dua HS. E-cadherin distribution and epithelial basement membrane characteristics of the normal human conjunctiva and cornea. Eye (Lond). 1997;11;607-612.
16. Yoshida Y, Ban Y, Kinoshita S. Tight junction transmembrane protein claudin subtype expression and distribution in human corneal and conjunctival epithelium. Invest Ophthalmol Vis Sci. 2009;50:2103-2108.
17. Yi X, Wang Y, Yu FS. Corneal epithelial tight junctions and their response to lipopolysaccharide challenge. Invest Ophthalmol Vis Sci. 2000;41:4093-4100.
18. Langbein L, Grund C, Kuhn C, et al. Tight junctions and compositionally related junctional structures in mammalian stratified epithelia and cell cultures derived therefrom. Eur J Cell Biol. 2002;81:419-435.
19. Moore P, Ogilvie J, Horridge E, Mellor IR, Clothier RH. The development of an innervated epithelial barrier model using a human corneal cell line and ND7/23 sensory neurons. Eur J Cell Biol. 2005;84:581-592.
20. Sugrue SP, Zieske JD. ZO1 in corneal epithelium: association to the zonula occludens and adherens junctions. Exp Eye Res. 1997;64:11-20.
21. Kimura K, Teranishi S, Fukuda K, Kawamoto K, Nishida T. Delayed disruption of barrier function in cultured human corneal epithelial cells induced by tumor necrosis factor-alpha in a manner dependent on NF-kappaB. Invest Ophthalmol Vis Sci. 2008;49:565-571.
22. Kimura K, Teranishi S, Nishida T. Interleukin-1beta-induced disruption of barrier function in cultured human corneal epithelial cells. Invest Ophthalmol Vis Sci. 2009;50:597-603.
23. Cordingley FT, Bianchi A, Hoffbrand AV, et al. Tumour necrosis factor as an autocrine tumour growth factor for chronic B-cell malignancies. Lancet. 1988;1:969-971.
24. Keadle TL, Usui N, Laycock KA, Miller JK, Pepose JS, Stuart PM. IL-1 and TNF-αlpha are important factors in the pathogenesis of murine recurrent herpetic stromal keratitis. Invest Ophthalmol Vis Sci. 2000;41:96-102.
25. Planck SR, Rich LF, Ansel JC, Huang XN, Rosenbaum JT. Trauma and alkali burns induce distinct patterns of cytokine gene expression in the rat cornea. Ocul Immunol Inflamm. 1997;5:95-100.
26. Luo L, Li DQ, Doshi A, Farley W, Corrales RM, Pflugfelder SC. Experimental dry eye stimulates production of inflammatory cytokines and MMP-9 and activates MAPK signaling pathways on the ocular surface. Invest Ophthalmol Vis Sci. 2004;45: 4293-4301.
27. Cameron JA. Shield ulcers and plaques of the cornea in vernal keratoconjunctivitis. Ophthalmology. 1995;102:985-993.
28. Stern ME, Pflugfelder SC. Inflammation in dry eye. Ocul Surf. 2004;2:124-130.
29. Lam H, Bleiden L, de Paiva CS, Farley W, Stern ME, Pflugfelder SC. Tear cytokine profiles in dysfunctional tear syndrome. Am J Ophthalmol. 2009;147:198-205. e191.
30. De Paiva CS, Corrales RM, Villarreal AL, et al. Corticosteroid and doxycycline suppress MMP-9 and inflammatory cytokine expression, MAPK activation in the corneal epithelium in experimental dry eye. Exp Eye Res. 2006;83:526-535.
31. Zhu L, Shen J, Zhang C, et al. Inflammatory cytokine expression on the ocular surface in the Botulium toxin B induced murine dry eye model. Mol Vis. 2009;15:250-258.
32. Arakawa T, Kobayashi K, Yoshikawa T, Tarnawski A. Rebamipide: overview of its mechanisms of action and efficacy in mucosal protection and ulcer healing. Dig Dis Sci. 1998;43: 5S-13S.
33. Katada K, Yoshida N, Isozaki Y, et al. Prevention by rebamipide of acute reflux esophagitis in rats. Dig Dis Sci. 2005;50:S97-S103.
34. Qi Z, Jie L, Haixia C, Xiaoying Z. Effect of rebamipide on quality of peptic ulcer healing in rat. Dig Dis Sci. 2009;54: 1876-1883.
35. Tanito M, Takanashi T, Kaidzu S, Yoshida Y, Ohira A. Cytoprotective effects of rebamipide and carteolol hydrochloride against ultraviolet B-induced corneal damage in mice. Invest Ophthalmol Vis Sci. 2003;44:2980-2985.
36. Araki-Sasaki K, Ohashi Y, Sasabe T, et al. An SV40-immortalized human corneal epithelial cell line and its characterization. Invest Ophthalmol Vis Sci. 1995;36:614-621.
37. Fujihara T, Murakami T, Fujita H, Nakamura M, Nakata K. Improvement of corneal barrier function by the P2Y(2) agonist INS365 in a rat dry eye model. Invest Ophthalmol Vis Sci. 2001;42:96-100.
38. Joh T, Takezono Y, Oshima T, et al. The protective effect of rebamipide on paracellular permeability of rat gastric epithelial cells. Aliment Pharmacol Ther. 2003;18:133-138.
39. Matysiak-Budnik T, Thomas-Collignon A, Megraud F, Heyman M. Alterations of epithelial permeability by Helicobacter and IL-1beta in vitro: protective effect of rebamipide. Dig Dis Sci. 2001;46:1558-1566.
40. Turner JR. 'Putting the squeeze' on the tight junction: understanding cytoskeletal regulation. Semin Cell Dev Biol. 2000;11:301-308.
41. Wittchen ES, Haskins J, Stevenson BR. Protein interactions at the tight junction. Actin has multiple binding partners, and ZO-1 forms independent complexes with ZO-2 and ZO-3. J Biol Chem. 1999;274:35179-35185.
42. Shen L, Turner JR. Actin depolymerization disrupts tight junctions via caveolae-mediated endocytosis. Mol Biol Cell. 2005;16:3919-3936.
43. Torii H, Kubota H, Ishihara H, Suzuki M. Cilostazol inhibits the redistribution of the actin cytoskeleton and junctional proteins on the blood-brain barrier under hypoxia/reoxygenation. Pharmacol Res. 2007;55:104-110.
44. Wang F, Graham WV, Wang Y, Witkowski ED, Schwarz BT, Turner JR. Interferon-gamma and tumor necrosis factor-alpha synergize to induce intestinal epithelial barrier dysfunction by up-regulating myosin light chain kinase expression. Am J Pathol. 2005;166:409-419.
45. Hahm KB, Kim DH, Lee KM, et al. Effect of long-term administration of rebamipide on Helicobacter pylori infection in mice. Aliment Pharmacol Ther. 2003;18:24-38.
46. Choe JY, Park KY, Lee SJ, Park SH, Kim SK. Rebamipide inhibits tumor necrosis factor-alpha-induced interleukin-8 expression by suppressing the NF-kappaB signal pathway in human umbilical vein endothelial cells. Inflamm Res. 59:1019-1026.
47. De Nicola R, Labbe A, Amar N, Dupas B, Baudouin C. In vivo confocal microscopy and ocular surface diseases: anatomicalclinical correlations [in French]. J Fr Ophtalmol. 2005;28:691-698.
48. Ikebe T, Takeuchi H, Jimi E, Beppu M, Shinohara M, Shirasuna K. Involvement of proteasomes in migration and matrix metalloproteinase-9 production of oral squamous cell carcinoma Int J Cancer. 1998;77:578-585.
49. Janowska-Wieczorek A, Marquez LA, Nabholtz JM, et al. Growth factors and cytokines upregulate gelatinase expression in bone marrow CD34(+) cells and their transmigration through reconstituted basement membrane. Blood. 1999;93: 3379-3390.
50. Pflugfelder SC, Farley W, Luo L, et al. Matrix metalloproteinase-9 knockout confers resistance to corneal epithelial barrier disruption in experimental dry eye. Am J Pathol. 2005;166: 61-71.
51. Andela VB, Gordon AH, Zotalis G, et al. NFkappaB: a pivotal transcription factor in prostate cancer metastasis to bone. Clin Orthop Relat Res. 2003;S75-85.
52. Das R, Philip S, Mahabeleshwar GH, Bulbule A, Kundu GC. Osteopontin: its role in regulation of cell motility and nuclear factor kappa B-mediated urokinase type plasminogen activator expression. IUBMB Life. 2005;57:441-447.
53. Moon SJ, Woo YJ, Jeong JH, et al. Rebamipide attenuates pain severity and cartilage degeneration in a rat model of osteoarthritis by downregulating oxidative damage and catabolic activity in chondrocytes. Osteoarthritis Cartilage. 2012;20:1426-1438.
54. Tsuji S, Kawai N, Tsujii M, Kawano S, Hori M. Review article: inflammation-related promotion of gastrointestinal carcinogenesis-a perigenetic pathway. Aliment Pharmacol Ther. 2003;18:82-89.
55. Fraser PA. The role of free radical generation in increasing cerebrovascular permeability. Free Radic Biol Med. 2011:51: 967-977.